Skip to content
Study details
Enrolling now

Acetazolamide for Treatment Resistant Schizophrenia

Vishwajit Nimgaonkar, MD PhD
NCT IDNCT04887792ClinicalTrials.gov data as of Apr 2026
Phase

Phase 1/2

Target enrollment

60

Study length

about 4.9 years

Ages

18–55

Locations

1 site in PA

About this study

Researchers are testing whether acetazolamide helps people with schizophrenia who haven't responded well to other treatments. It involves comparing acetazolamide to a placebo (an inactive pill). The trial will last about 1793 days and involve approximately 60 participants.

Based on ClinicalTrials.gov records.

What participants do

  • 1.Take Acetazolamide
  • 2.Take Placebo
PhasePhase 1/Phase 2
DrugAcetazolamide
Routeinjection
Primary goalChange in positive symptoms

Participation effort

Estimated from trial records. Details can vary by site.

Time + visits
Low8%
Logistics
Moderate50%

Logistics difficulty varies by site location and availability.

Trial highlights

Treatment details

Auto-extracted from trial records to preview treatments and outcomes.

Drug classes

acetazolamide

Drug routes

injection, intravenous

Endpoints

Primary: Change in positive symptoms

Secondary: Cognition, Measure of satisfaction with one's Quality of Life (Quality of Life Scale/QOLS)

Body systems

Psychiatry / Mental Health